The cumulative HR for OS was 1.93 (95% CI, 1.56–2.38) (Fig. 5A), and for RFS was 1.95 (95% CI, 1.31–2.91) (Fig. 5B), confirming SMAD4 mutations as a detrimental prognostic factor in CRC patients undergoing liver metastasectomy. This evidence concerns the gene SMAD4 and colorectal carcinoma.